NEWS

November 19, 2020
Outlook Therapeutics Announces Creation of Global Retina Advisory Council
More
November 11, 2020
Virtual KOL Roundtable Recap: Outlook Therapeutics and Firas Rahhal, MD, Discussed wet AMD Treatment Landscape and ONS-5010/LYTENAVA™
More

Outlook Therapeutics…

…is a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and branch retinal vein occlusion (BRVO).

ABOUT ONS-5010

ONS-5010/ LYTENAVA™ (bevacizumab-vikg) is an investigational ophthalmic formulation of bevacizumab-vikg under development to be administered as an intravitreal injection for the treatment of wet AMD and other retinal diseases. Bevacizumab is a full-length, humanized anti-VEGF (Vascular Endothelial Growth Factor) recombinant monoclonal antibody (or mAb) that inhibits VEGF and associated angiogenic activity.

ONS-5010 is currently being evaluated in our Phase 3 program for wet AMD and is expected to be filed with the FDA as a new BLA for this ophthalmic indication. Outlook Therapeutics also intends to commence additional clinical trials for ONS-5010 in DME and BRVO.

If approved, ONS-5010 will be the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg to treat retinal diseases.